New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

This chapter focuses on new antithrombotic drugs that are in phase II or III clinical testing. Development of these new agents was prompted by limitations of existing antiplatelet, anticoagulant, or fibrinolytic drugs. Addressing these unmet needs, this chapter (1) outlines the rationale for development of new antithrombotic agents, (2) describes the new antiplatelet, anticoagulant, and fibrinolytic drugs, and (3) provides clinical perspectives on the opportunities and challenges faced by these novel agents.

[1]  Patrice Cacoub,et al.  Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. , 2006, The New England journal of medicine.

[2]  Y. Terada,et al.  Tolerability, pharmacokinetics, and pharmacodynamics of DX‐9065a, a new synthetic potent anticoagulant and specific factor Xa inhibitor, in healthy male volunteers , 1999, Clinical pharmacology and therapeutics.

[3]  G. Pineo,et al.  The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement 1 , 2007, Journal of thrombosis and haemostasis : JTH.

[4]  R. Collins,et al.  Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial , 2005, The Lancet.

[5]  B. Jilma,et al.  Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases , 2010, British journal of pharmacology.

[6]  E. Plow,et al.  On the Mechanism of the Antifibrinolytic Activity of Plasma Carboxypeptidase B* , 1997, The Journal of Biological Chemistry.

[7]  P. Verhallen,et al.  An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model. , 2000, Thrombosis research.

[8]  M. Milani,et al.  Effects of picotamide, an antiplatelet agent, on cardiovascular, events in 438 claudicant patients with diabetes: a retrospective analysis of the ADEP study. , 2003, British journal of clinical pharmacology.

[9]  I. Baskova,et al.  Destabilase, the novel epsilon-(gamma-Glu)-Lys isopeptidase with thrombolytic activity. , 1991, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[10]  A. Paccaly,et al.  Pharmacodynamic markers in the early clinical assessment of otamixaban, a direct factor Xa inhibitor , 2005, Thrombosis and Haemostasis.

[11]  L. Christiaens,et al.  Aspirin resistance: definitions, mechanisms, prevalence, and clinical significance. , 2006, Current pharmaceutical design.

[12]  R. Ádány,et al.  Novel aspects of blood coagulation factor XIII. I. Structure, distribution, activation, and function. , 1996, Critical reviews in clinical laboratory sciences.

[13]  R. Peters,et al.  Recombinant nematode anticoagulant protein c2, an inhibitor of the tissue factor/factor VIIa complex, in patients undergoing elective coronary angioplasty. , 2003, Journal of the American College of Cardiology.

[14]  S. Steinhubl,et al.  G-Protein–Coupled Receptors as Signaling Targets for Antiplatelet Therapy , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[15]  Kevin P. Bliden,et al.  Clopidogrel for Coronary Stenting Response Variability, Drug Resistance, and the Effect of Pretreatment Platelet Reactivity , 2003, Circulation.

[16]  C. Toombs.  Alfimeprase: Pharmacology of a Novel Fibrinolytic Metalloproteinase for Thrombolysis , 2001, Pathophysiology of Haemostasis and Thrombosis.

[17]  M. Prins,et al.  A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery , 2007, Journal of thrombosis and haemostasis : JTH.

[18]  Deepak L. Bhatt,et al.  Factor Xa inhibitors in acute coronary syndromes: moving from mythology to reality , 2005, Journal of thrombosis and haemostasis : JTH.

[19]  B. Eriksson,et al.  Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement. , 2007, Thrombosis research.

[20]  J. Necciari,et al.  Pharmacokinetics and Tolerance of the Natural Pentasaccharide (SR90107/ORG31540) with High Affinity to Antithrombin III in Man , 1995, Thrombosis and Haemostasis.

[21]  G. Powis,et al.  Inositol Analogs as Potential Anticancer Therapeutics , 1994, Current Medicinal Chemistry.

[22]  G. Feuerstein,et al.  Comparing the antithrombotic efficacy of a humanized anti-factor IX(a) monoclonal antibody (SB 249417) to the low molecular weight heparin enoxaparin in a rat model of arterial thrombosis. , 2000, Thrombosis research.

[23]  Vivian Gu,et al.  Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. , 2008, The New England journal of medicine.

[24]  K. Rathgen,et al.  The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. , 2007, British journal of clinical pharmacology.

[25]  Marc P. Bonaca,et al.  Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. , 2009, American heart journal.

[26]  B. Muehlenweg,et al.  Inhibition of the invasion capacity of carcinoma cells by WX‐UK1, a novel synthetic inhibitor of the urokinase‐type plasminogen activator system , 2004, International journal of cancer.

[27]  Gregg W Stone,et al.  Platelet inhibition with cangrelor in patients undergoing PCI. , 2009, The New England journal of medicine.

[28]  Deepak L. Bhatt,et al.  Incomplete Inhibition of Thromboxane Biosynthesis by Acetylsalicylic Acid: Determinants and Effect on Cardiovascular Risk , 2008, Circulation.

[29]  A. Kastrati,et al.  Absorption, Metabolization, and Antiplatelet Effects of 300-, 600-, and 900-mg Loading Doses of Clopidogrel: Results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial , 2005, Circulation.

[30]  B. Sobel,et al.  Inhibition of Endothelial Cell Expression of Plasminogen Activator Inhibitor Type-1 by Gemfibrozil , 1993, Thrombosis and Haemostasis.

[31]  L. Guerrero,et al.  M118 – A rationally engineered low-molecular-weight heparin designed specifically for the treatment of acute coronary syndromes , 2009, Thrombosis and Haemostasis.

[32]  H. Graefe,et al.  The Oral Serine Protease Inhibitor WX-671 – First Experience in Patients with Advanced Head and Neck Carcinoma , 2008, Breast Care.

[33]  Steven H. Huang,et al.  Ancylostoma caninum anticoagulant peptide: a hookworm-derived inhibitor of human coagulation factor Xa. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[34]  P. Corso,et al.  Clopidogrel administration prior to coronary artery bypass grafting surgery: the cardiologist's panacea or the surgeon's headache? , 2005, European heart journal.

[35]  R. Wunderink,et al.  A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia , 2009, Critical care.

[36]  L. Cudd,et al.  Cangrelor for Treatment of Coronary Thrombosis , 2006, The Annals of pharmacotherapy.

[37]  D. Ward,et al.  Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study , 2008, Journal of thrombosis and haemostasis : JTH.

[38]  M Gent,et al.  Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. , 2003, The New England journal of medicine.

[39]  A. Rezaie,et al.  Prothrombin protects factor Xa in the prothrombinase complex from inhibition by the heparin-antithrombin complex. , 2001, Blood.

[40]  E. Antman,et al.  Bolus fibrinolytic therapy in acute myocardial infarction. , 2001, JAMA.

[41]  J. Herbert,et al.  Comparative effects of two direct and indirect factor Xa inhibitors on free and clot-bound prothrombinase. , 1997, The Journal of pharmacology and experimental therapeutics.

[42]  S. Yusuf,et al.  Effects of Aspirin Dose When Used Alone or in Combination With Clopidogrel in Patients With Acute Coronary Syndromes: Observations From the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study , 2003, Circulation.

[43]  W. Ruf,et al.  Role of Zymogen and Activated Factor X as Scaffolds for the Inhibition of the Blood Coagulation Factor VIIa-Tissue Factor Complex by Recombinant Nematode Anticoagulant Protein c2* , 2001, The Journal of Biological Chemistry.

[44]  M. Adler,et al.  3-Mercaptopropionic acids as efficacious inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa). , 2007, Bioorganic & medicinal chemistry letters.

[45]  P. Gurbel,et al.  Clopidogrel resistance: implications for coronary stenting. , 2006, Current pharmaceutical design.

[46]  B. Sobel,et al.  Attenuation of the synthesis of plasminogen activator inhibitor type 1 by niacin. A potential link between lipid lowering and fibrinolysis. , 1995, Circulation.

[47]  J Ean,et al.  Efficacy and safety of recombinant human activated protein C for severe sepsis. , 2001, The New England journal of medicine.

[48]  W. Greenlee,et al.  Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. , 2008, Journal of medicinal chemistry.

[49]  V. Marder,et al.  Direct fibrinolytic agents: biochemical attributes, preclinical foundation and clinical potential , 2010, Journal of thrombosis and haemostasis : JTH.

[50]  M. Nesheim,et al.  Reversible inhibitors of TAFIa can both promote and inhibit fibrinolysis , 2003, Journal of thrombosis and haemostasis : JTH.

[51]  M. Gent,et al.  A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT) , 2008, Thrombosis and Haemostasis.

[52]  P. Watkins,et al.  Contribution of Hepatic Cytochrome P450 3A4 Metabolic Activity to the Phenomenon of Clopidogrel Resistance , 2004, Circulation.

[53]  S. Yusuf,et al.  Aspirin-Resistant Thromboxane Biosynthesis and the Risk of Myocardial Infarction, Stroke, or Cardiovascular Death in Patients at High Risk for Cardiovascular Events , 2002, Circulation.

[54]  E. Antman,et al.  Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial , 2009, The Lancet.

[55]  Mark J. Antonino,et al.  Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease: The ONSET/OFFSET Study , 2009, Circulation.

[56]  D. Lawrence,et al.  The Acid Stabilization of Plasminogen Activator Inhibitor-1 Depends on Protonation of a Single Group That Affects Loop Insertion into β-Sheet A (*) , 1995, The Journal of Biological Chemistry.

[57]  Mosesson Mw.  The roles of fibrinogen and fibrin in hemostasis and thrombosis. , 1992 .

[58]  F. Violi,et al.  Effect of Picotamide on the Clinical Progression of Peripheral Vascular Disease A Double‐Blind Placebo‐Controlled Study , 1993 .

[59]  S. Lévy,et al.  Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial , 2008, The Lancet.

[60]  B. Jude,et al.  The specific thromboxane receptor antagonist S18886: pharmacokinetic and pharmacodynamic studies , 2005, Journal of thrombosis and haemostasis : JTH.

[61]  S. Warach,et al.  Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion–diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study , 2009, The Lancet Neurology.

[62]  Deepak L. Bhatt,et al.  Intravenous platelet blockade with cangrelor during PCI. , 2009, The New England journal of medicine.

[63]  P. Armstrong,et al.  Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intra , 2009, American heart journal.

[64]  S. Warrington,et al.  Pharmacokinetics and pharmacodynamics of BB‐10153 1 , a thrombin‐activatable plasminogen, in healthy volunteers , 2005, Journal of thrombosis and haemostasis : JTH.

[65]  P. Gorelick,et al.  Aspirin Plus Dipyridamole Versus Aspirin for Prevention of Vascular Events After Stroke or TIA: A Meta-Analysis , 2008, Stroke.

[66]  H. Diener,et al.  Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial , 2004, The Lancet.

[67]  P. Sandset,et al.  Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. , 2006, European heart journal.

[68]  M. Nesheim,et al.  The Use of Prothrombin(S525C) Labeled with Fluorescein to Directly Study the Inhibition of Prothrombinase by Antithrombin during Prothrombin Activation* , 2001, The Journal of Biological Chemistry.

[69]  Samuel Z Goldhaber,et al.  Treatment of Proximal Deep-Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939): The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) Study , 2007, Circulation.

[70]  L. Wood,et al.  Thrombolytic activity of BB‐10153, a thrombin‐activatable plasminogen , 2005, Journal of thrombosis and haemostasis : JTH.

[71]  Á. Chamorro,et al.  The Prevention of Cerebrovascular and Cardiovascular Events of Ischemic Origin with Terutroban in Patients with a History of Ischemic Stroke or Transient Ischemic Attack (PERFORM) Study: Baseline Characteristics of the Population , 2009, Cerebrovascular Diseases.

[72]  V. Hasselblad,et al.  Initial experience with factor‐Xa inhibition in percutaneous coronary intervention: the XaNADU‐PCI Pilot , 2004, Journal of thrombosis and haemostasis : JTH.

[73]  J. Weitz,et al.  Characterization of the Interactions of Plasminogen and Tissue and Vampire Bat Plasminogen Activators with Fibrinogen, Fibrin, and the Complex of d-Dimer Noncovalently Linked to Fragment E* , 1998, The Journal of Biological Chemistry.

[74]  P. Meroni,et al.  Impaired bradykinin response to ischaemia and exercise in patients with mild congestive heart failure during angiotensin-converting enzyme treatment : relationships with endothelial function, coagulation and inflammation , 2005 .

[75]  P. Verhamme,et al.  A human monoclonal antibody inhibiting partially factor VIII activity reduces thrombus growth in baboons , 2009, Journal of thrombosis and haemostasis : JTH.

[76]  S. Yusuf,et al.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. , 2001, The New England journal of medicine.

[77]  G. Pelle,et al.  Improved endothelial function by the thromboxane A2 receptor antagonist S 18886 in patients with coronary artery disease treated with aspirin. , 2003, Journal of the American College of Cardiology.

[78]  E. Topol,et al.  Inducible carboxypeptidase activity. A role in clot lysis in vivo. , 1996, Circulation.

[79]  D. Gustafsson.  Oral direct thrombin inhibitors in clinical development , 2003, Journal of internal medicine.

[80]  S. Murphy,et al.  Dose escalation trial of the efficacy, safety, and pharmacokinetics of a novel fibrinolytic agent, BB-10153, in patients with ST elevation MI: Results of the TIMI 31 trial , 2006, Journal of Thrombosis and Thrombolysis.

[81]  A. Mattioli,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[82]  J. T. ten Cate,et al.  Novel low-molecular-weight inhibitor of PAI-1 (XR5118) promotes endogenous fibrinolysis and reduces postthrombolysis thrombus growth in rabbits. , 1997, Circulation.

[83]  杨靓,et al.  Aspirin resistance , 2004 .

[84]  Sonia S Anand,et al.  Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease. , 2004, JAMA.

[85]  A. Frick,et al.  Direct and rapid inhibition of factor Xa by otamixaban: A pharmacokinetic and pharmacodynamic investigation in patients with coronary artery disease , 2006, Clinical pharmacology and therapeutics.

[86]  Mark D. Williams,et al.  Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial , 2007, The Lancet.

[87]  R. Collins,et al.  Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. , 2009, Lancet.

[88]  Persist investigators.  A novel long‐acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation , 2004, Journal of thrombosis and haemostasis : JTH.

[89]  P. Armstrong,et al.  First experience with direct, selective factor Xa inhibition in patients with non‐ST‐elevation acute coronary syndromes: results of the XaNADU‐ACS Trial , 2005, Journal of thrombosis and haemostasis : JTH.

[90]  B. Eriksson,et al.  Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development , 2009, Clinical pharmacokinetics.

[91]  M. Bernatowicz,et al.  Peptide-derived protease-activated receptor-1 (PAR-1) antagonists. , 2003, Current medicinal chemistry. Cardiovascular and hematological agents.

[92]  B. Mertens,et al.  Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. , 2007, American heart journal.

[93]  V. Hasselblad,et al.  Effect of the novel direct factor Xa inhibitor DX-9065a on thrombin generation and inhibition among patients with stable atherosclerotic coronary artery disease. , 2006, Thrombosis research.

[94]  William M. Lee,et al.  Hepatic Findings in Long-Term Clinical Trials of Ximelagatran , 2005, Drug safety.

[95]  A Abrahamsson,et al.  The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. , 2001, Thrombosis research.

[96]  D. Lawrence,et al.  Peptide-mediated inactivation of recombinant and platelet plasminogen activator inhibitor-1 in vitro. , 1995, The Journal of clinical investigation.

[97]  F. Taylor,et al.  Role of tissue factor and factor VIIa in the coagulant and inflammatory response to LD100 Escherichia coli in the baboon. , 1996, Haemostasis.

[98]  S. Warach,et al.  The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): A Phase II MRI-Based 9-Hour Window Acute Stroke Thrombolysis Trial With Intravenous Desmoteplase , 2005, Stroke.

[99]  W. Mueck,et al.  Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor xa inhibitor--in healthy subjects. , 2007, International journal of clinical pharmacology and therapeutics.

[100]  E. Topol,et al.  Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. , 1995, Circulation.

[101]  D. Atar,et al.  Dyspnoea after antiplatelet agents: the AZD6140 controversy , 2007, International journal of clinical practice.

[102]  E. Antman,et al.  Selection of the optimal reperfusion strategy for STEMI: does time matter? , 2006, European heart journal.

[103]  Steven Warach,et al.  Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): Evidence of Safety and Efficacy 3 to 9 Hours After Stroke Onset , 2006, Stroke.

[104]  B. Eriksson,et al.  Oral, direct Factor Xa inhibition with BAY 59‐7939 for the prevention of venous thromboembolism after total hip replacement , 2006, Journal of thrombosis and haemostasis : JTH.

[105]  D. Rijken,et al.  Fibrinolytic efficacy of Amediplase, Tenecteplase and scu-PA in different external plasma clot lysis models , 2006, Thrombosis and Haemostasis.

[106]  C. Cannon,et al.  Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. , 2007, Journal of the American College of Cardiology.

[107]  C. Sprung,et al.  Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. , 2003, JAMA.

[108]  G. Raskob,et al.  Fondaparinux or Enoxaparin for the Initial Treatment of Symptomatic Deep Venous Thrombosis , 2004, Annals of Internal Medicine.

[109]  Catherine Sudlow,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[110]  K. Mahaffey,et al.  Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study , 2009, The Lancet.

[111]  J. Foekens,et al.  Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1 , 2005, Thrombosis and Haemostasis.

[112]  G. Lip,et al.  Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists , 2009, European heart journal.

[113]  R. G. Humphries,et al.  Preclinical and Clinical Studies with Selective Reversible Direct P2Y12 Antagonists , 2005, Seminars in thrombosis and hemostasis.

[114]  M Gent,et al.  Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high‐risk abdominal surgery , 2005, The British journal of surgery.

[115]  G. Raskob,et al.  Dose-Response Study of Recombinant Factor VIIa/Tissue Factor Inhibitor Recombinant Nematode Anticoagulant Protein c2 in Prevention of Postoperative Venous Thromboembolism in Patients Undergoing Total Knee Replacement , 2001, Circulation.

[116]  H. Buller,et al.  Direct Thrombin Inhibitors in Acute Coronary Syndromes: Present and Future , 2002, Circulation.

[117]  C. Kluft,et al.  Stabilization Versus Inhibition of TAFIa by Competitive Inhibitors in Vitro * , 2003, The Journal of Biological Chemistry.

[118]  A. A. Parsons,et al.  Inhibition of Factor IX(a) Is Protective in a Rat Model of Thromboembolic Stroke , 2002, Stroke.

[119]  M. Gent,et al.  Rivaroxaban for thromboprophylaxis after orthopaedic surgery: Pooled analysis of two studies , 2007, Thrombosis and Haemostasis.

[120]  S. Yusuf,et al.  Benefits and Risks of the Combination of Clopidogrel and Aspirin in Patients Undergoing Surgical Revascularization for Non–ST-Elevation Acute Coronary Syndrome: The Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial , 2004, Circulation.

[121]  H. Homesley,et al.  Phase II trial of alfimeprase, a novel-acting fibrin degradation agent, for occluded central venous access devices. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[122]  A. Skene,et al.  Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. , 2005, The New England journal of medicine.

[123]  D. Clement.  A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996 .

[124]  Claes Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.

[125]  S. Frostick,et al.  Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE‐MODEL randomized trial , 2007, Journal of thrombosis and haemostasis : JTH.

[126]  E. Antman,et al.  Randomized Comparison of Prasugrel (CS-747, LY640315), a Novel Thienopyridine P2Y12 Antagonist, With Clopidogrel in Percutaneous Coronary Intervention: Results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)–TIMI 26 Trial , 2005, Circulation.

[127]  A. Turpie.  Oral, Direct Factor Xa Inhibitors in Development for the Prevention and Treatment of Thromboembolic Diseases , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[128]  Deepak L. Bhatt,et al.  Assessing the Current Role of Platelet Function Testing , 2008, Clinical cardiology.

[129]  W. Funk,et al.  Alfimeprase: a novel recombinant direct-acting fibrinolytic , 2006, Expert opinion on biological therapy.

[130]  S. Finney,et al.  Tridegin, a new peptidic inhibitor of factor XIIIa, from the blood-sucking leech Haementeria ghilianii. , 1997, The Biochemical journal.

[131]  G. Raskob,et al.  Idraparinux versus standard therapy for venous thromboembolic disease. , 2007, The New England journal of medicine.

[132]  B. Sullenger,et al.  A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[133]  M. Prins,et al.  Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial , 2006, BMJ : British Medical Journal.

[134]  R. Postier,et al.  Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: A multicenter, randomized, placebo-controlled, single-blind, dose escalation study , 2001, Critical care medicine.

[135]  B. Eriksson,et al.  Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. , 2002, Archives of internal medicine.

[136]  R. Colman,et al.  Hemostasis and Thrombosis: Basic Principles and Clinical Practice , 1988 .

[137]  A. Dmitrienko,et al.  A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement , 2007, Journal of thrombosis and haemostasis : JTH.

[138]  M. Gent,et al.  BAY 59‐7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose‐ranging study , 2005, Journal of thrombosis and haemostasis : JTH.

[139]  B. Sullenger,et al.  RNA aptamers as reversible antagonists of coagulation factor IXa , 2002, Nature.

[140]  R. Kim,et al.  Personalized medicine and antiplatelet therapy: ready for prime time? , 2009, European heart journal.

[141]  P. Modesti,et al.  Binding kinetics and antiplatelet activities of picotamide, a thromboxane A2 receptor antagonist , 1994, British journal of pharmacology.

[142]  H. Büller,et al.  A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial , 2005, Journal of thrombosis and haemostasis : JTH.

[143]  R. Giugliano,et al.  Recombinant nematode anticoagulant protein c2 in patients with non-ST-segment elevation acute coronary syndrome: the ANTHEM-TIMI-32 trial. , 2007, Journal of the American College of Cardiology.

[144]  R. Rossaint,et al.  Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. , 2005, The New England journal of medicine.

[145]  Pol F Boudes,et al.  The challenges of new drugs benefits and risks analysis: lessons from the ximelagatran FDA Cardiovascular Advisory Committee. , 2006, Contemporary clinical trials.

[146]  Michael Becka,et al.  Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects , 2005, European Journal of Clinical Pharmacology.

[147]  G. Vlasuk,et al.  Assembly of the prothrombinase complex enhances the inhibition of bovine factor Xa by tick anticoagulant peptide. , 1994, Biochemistry.

[148]  W. Weaver,et al.  Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. , 2006, American heart journal.

[149]  J. Douketis,et al.  Dose–response study of recombinant human soluble thrombomodulin (ART‐123) in the prevention of venous thromboembolism after total hip replacement , 2005, Journal of thrombosis and haemostasis : JTH.

[150]  W. Humphreys,et al.  Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans , 2009, Drug Metabolism and Disposition.

[151]  R. Dwek,et al.  Variable region heavy chain glycosylation determines the anticoagulant activity of a factor VIII antibody , 2006, Journal of thrombosis and haemostasis : JTH.

[152]  K. Winters,et al.  A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans. , 2007, British journal of clinical pharmacology.

[153]  J. Herbert,et al.  DX 9065A a novel, synthetic, selective and orally active inhibitor of factor Xa: in vitro and in vivo studies. , 1996, The Journal of pharmacology and experimental therapeutics.

[154]  W. Jusko,et al.  Pharmacokinetic and pharmacodynamic modeling of humanized anti–factor IX antibody (SB 249417) in humans , 2002, Clinical pharmacology and therapeutics.

[155]  A. Gils,et al.  Comparative study of inhibitory antibody derivatives towards thrombin activatable fibrinolysis inhibitor , 2009, Thrombosis and Haemostasis.

[156]  A. Nicolaides,et al.  S-18886 Servier. , 2002, Current opinion in investigational drugs.

[157]  F. Violi,et al.  Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study. , 2004, European heart journal.

[158]  J. Erhardt,et al.  A comparison of the β‐D‐xyloside, odiparcil, to warfarin in a rat model of venous thrombosis , 2006, Journal of thrombosis and haemostasis : JTH.

[159]  J. Herbert,et al.  SR123781A, a Synthetic Heparin Mimetic , 2001, Thrombosis and Haemostasis.

[160]  D. McTavish,et al.  A Review of its Pharmacological Properties and Clinical Efficacy in the Management of Acute Myocardial Infarction , 2012 .

[161]  S. Yusuf,et al.  Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. , 2006, JAMA.

[162]  S. Steinhubl,et al.  Phase 1b Randomized Study of Antidote-Controlled Modulation of Factor IXa Activity in Patients With Stable Coronary Artery Disease , 2008, Circulation.

[163]  J. Berger,et al.  Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. , 2009, JAMA.

[164]  S. Steinhubl,et al.  First-in-Human Experience of an Antidote-Controlled Anticoagulant Using RNA Aptamer Technology: A Phase 1a Pharmacodynamic Evaluation of a Drug-Antidote Pair for the Controlled Regulation of Factor IXa Activity , 2006, Circulation.

[165]  J. Weitz,et al.  Exosites 1 and 2 Are Essential for Protection of Fibrin-bound Thrombin from Heparin-catalyzed Inhibition by Antithrombin and Heparin Cofactor II* , 1999, The Journal of Biological Chemistry.

[166]  S. Colon,et al.  Pharmacokinetics and anticoagulant properties of the factor VIIa-tissue factor inhibitor recombinant Nematode Anticoagulant Protein c2 following subcutaneous administration in man , 2003, Thrombosis and Haemostasis.

[167]  B. Eriksson,et al.  Superiority of fondaparinux over enoxaparin in preventing venous thromboembolism in major orthopedic surgery using different efficacy end points. , 2004, Chest.

[168]  S. Frostick,et al.  Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial , 2007, The Lancet.

[169]  P. Klement,et al.  A Novel Approach to Arterial Thrombolysis , 1999 .

[170]  S. Finney,et al.  Tridegin, a Novel Peptidic Inhibitor of Factor XIIIa from the Leech, Haementeria ghilianii, Enhances Fibrinolysis In Vitro , 1997, Thrombosis and Haemostasis.

[171]  C. Vlahos,et al.  Stable expression of a secretable deletion mutant of recombinant human thrombomodulin in mammalian cells. , 1990, The Journal of biological chemistry.

[172]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.

[173]  G. Raskob,et al.  Extended prophylaxis of venous thromboembolism with idraparinux. , 2007, The New England journal of medicine.

[174]  F. Burzotta,et al.  Ximelagatran/melagatran against conventional anticoagulation: a meta-analysis based on 22,639 patients. , 2007, International journal of cardiology.

[175]  G. Raskob,et al.  Apixaban or enoxaparin for thromboprophylaxis after knee replacement. , 2009, The New England journal of medicine.

[176]  Salim Yusuf,et al.  Comparison of fondaparinux and enoxaparin in acute coronary syndromes. , 2006, The New England journal of medicine.

[177]  T. Lecompte.  Résistance à l’aspirine, G.J. Hankey, J. Eikelboom, in: Lancet, 367. (2006), 606 , 2006 .

[178]  J. Herbert,et al.  Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. , 2005, Seminars in thrombosis and hemostasis.

[179]  S. Lukyanov,et al.  Genes from the medicinal leech (Hirudo medicinalis) coding for unusual enzymes that specifically cleave endo-ɛ(γ-Glu)-Lys isopeptide bonds and help to dissolve blood clots , 1996, Molecular and General Genetics MGG.

[180]  J. Caprini,et al.  The Oral Direct Thrombin Inhibitor, Dabigatran Etexilate, is Effective and Safe for Prevention of Major Venous Thromboembolism After Major Orthopedic Surgery , 2008 .

[181]  L. Millet,et al.  Effect of SanOrg123781A, a synthetic hexadecasaccharide, on clot‐bound thrombin and factor Xa in vitro and in vivo , 2003, Journal of thrombosis and haemostasis : JTH.

[182]  Deepak L. Bhatt,et al.  Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial , 2009, Circulation.

[183]  G. Avgerinos,et al.  Production and clinical development of a Hansenula polymorpha-derived PEGylated hirudin. , 2001, Seminars in thrombosis and hemostasis.

[184]  J. Weitz,et al.  Emerging anticoagulants for the treatment of venous thromboembolism , 2006, Thrombosis and Haemostasis.

[185]  B. Eriksson,et al.  A Once-Daily, Oral, Direct Factor Xa Inhibitor, Rivaroxaban (BAY 59-7939), for Thromboprophylaxis After Total Hip Replacement , 2006, Circulation.

[186]  Timothy Henry,et al.  Randomized, Double-Blind, Dose-Ranging Study of Otamixaban, a Novel, Parenteral, Short-Acting Direct Factor Xa Inhibitor, in Percutaneous Coronary Intervention: The SEPIA-PCI Trial , 2007, Circulation.

[187]  S. Gardell,et al.  Vampire Bat Salivary Plasminogen Activator Evokes Minimal Bleeding Relative to Tissue-Type Plasminogen Activator as Assessed by a Rabbit Cuticle Bleeding Time Model , 1995, Thrombosis and Haemostasis.

[188]  P. Wong,et al.  Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro , 2009, Thrombosis and Haemostasis.

[189]  K. Goa,et al.  Tenecteplase: a review of its pharmacology and therapeutic efficacy in patients with acute myocardial infarction. , 2001, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[190]  H. Neubauer,et al.  Thienopyridines and statins: assessing a potential drug-drug interaction. , 2006, Current pharmaceutical design.

[191]  S. Iturria,et al.  Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel , 2007, Journal of thrombosis and haemostasis : JTH.

[192]  M. Crowther,et al.  Direct thrombin inhibitors. , 2002, Thrombosis research.

[193]  J. Herbert,et al.  Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. , 1998, Blood.